TY - JOUR
T1 - Effectiveness of Cimetidine as Adjuvant Therapy in the Treatment of Acute-Extrinsic Atopic Dermatitis
T2 - A Double-Blind Randomized Controlled Trial
AU - Novianto, Endi
AU - Jacoeb, Tjut N.A.
AU - Indriatmi, Wresti
AU - Suhendro,
AU - Setiabudy, Rianto
AU - Setiabudy, Rahajuningsih D.
AU - Abdullah, Murdani
AU - Rengganis, Iris
AU - Suwarsa, Oki
AU - Soebaryo, Retno W.
N1 - Funding Information:
No funding or sponsorship was received for this study or publication of this article. The Rapid Service Fee was funded by the authors.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/2/17
Y1 - 2022/2/17
N2 - Introduction: Acute extrinsic atopic dermatitis (AD) requires long-term treatment. Cimetidine could be used as an adjuvant therapy for acute-extrinsic AD due to immunomodulatory effects. This study aims to assess the effectiveness of cimetidine as an adjuvant to standard treatment in acute extrinsic AD. Methods: This is a double-blind randomized controlled trial involving 26 AD patients aged 12–60 years from 2017 to 2020. Effectiveness of cimetidine was assessed by comparing SCORing Atopic Dermatitis (SCORAD) and objective SCORAD changes in both groups at week 2, 4, 6, and 8. Serum levels of immunoglobulin E (IgE), interferon (IFN)-γ, interleukin (IL)-12, and IL-4 were also documented. Results: Significant differences were observed in SCORAD changes at week 2, 4, 6, and 8 (p = 0.004; p = 0.001; p < 0.001; and p < 0.001 respectively), objective SCORAD changes at week 2, 4, 6, and 8 (p = 0.004, p = 0.001, p < 0.001, and p < 0.001 respectively), and IgE level changes at week 8 (p = 0.002) between the two groups. However, there were no significant changes in IFN-γ, IL-12, and IL-4 levels between the two groups. Conclusion: Cimetidine is a safe and effective adjuvant therapy for acute-extrinsic AD. Trial Registration: NCT04018131.
AB - Introduction: Acute extrinsic atopic dermatitis (AD) requires long-term treatment. Cimetidine could be used as an adjuvant therapy for acute-extrinsic AD due to immunomodulatory effects. This study aims to assess the effectiveness of cimetidine as an adjuvant to standard treatment in acute extrinsic AD. Methods: This is a double-blind randomized controlled trial involving 26 AD patients aged 12–60 years from 2017 to 2020. Effectiveness of cimetidine was assessed by comparing SCORing Atopic Dermatitis (SCORAD) and objective SCORAD changes in both groups at week 2, 4, 6, and 8. Serum levels of immunoglobulin E (IgE), interferon (IFN)-γ, interleukin (IL)-12, and IL-4 were also documented. Results: Significant differences were observed in SCORAD changes at week 2, 4, 6, and 8 (p = 0.004; p = 0.001; p < 0.001; and p < 0.001 respectively), objective SCORAD changes at week 2, 4, 6, and 8 (p = 0.004, p = 0.001, p < 0.001, and p < 0.001 respectively), and IgE level changes at week 8 (p = 0.002) between the two groups. However, there were no significant changes in IFN-γ, IL-12, and IL-4 levels between the two groups. Conclusion: Cimetidine is a safe and effective adjuvant therapy for acute-extrinsic AD. Trial Registration: NCT04018131.
KW - Atopic dermatitis
KW - Cimetidine
KW - Efficacy
KW - IgE level
KW - SCORAD
UR - http://www.scopus.com/inward/record.url?scp=85124758668&partnerID=8YFLogxK
U2 - 10.1007/s13555-022-00688-z
DO - 10.1007/s13555-022-00688-z
M3 - Article
AN - SCOPUS:85124758668
SN - 2193-8210
VL - 12
SP - 715
EP - 726
JO - Dermatology and Therapy
JF - Dermatology and Therapy
IS - 3
ER -